Research programme: nephritis therapy - ChemoCentryx
Latest Information Update: 24 Jul 2007
At a glance
- Originator ChemoCentryx
- Class Small molecules
- Mechanism of Action Chemokine receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Nephritis
Most Recent Events
- 11 Jul 2003 Preclinical trials in Nephritis in USA (unspecified route)